Loading patent…
OwnerRyuichi Morishita, Motokuni Aoki +5inventors
InventorsRyuichi Morishita, Motokuni Aoki, Toshio Ogihara, Tomio Kawasaki, Hirofumi Makino, Takashi Shishikura, Akihiro Koyanagi
Estimating the term…
A pharmaceutical composition for treating and preventing diseases, disorders and/or conditions of airway inflammation, airway stenosis or nasal cavity inflammation caused by the expression of a gene regulated by NF-kappaB which contains an NF-kappaB decoy and a pharmaceutically acceptable carrier. The above diseases may be asthma, COPD or rhinitis. Moreover, the above diseases may be diseases caused by an eosinophil abnormality (for example, asthma, rhinitis and COPD). The pharmaceutically acceptable carrier may be a hydrophilic polymer, a liposome and so on.
A pharmaceutical composition for treating and/or preventing a disease, disorder and/or condition of the respiratory system due to expression of a gene regulated by NF-κB, comprising an NF-κB decoy and a pharmaceutically acceptable carrier.
A composition for treating and/or preventing a disease, disorder and/or condition of the respiratory system relating to an eosinophil abnormality, comprising NF-κB decoy and a pharmaceutically acceptable carrier.
A method for manufacturing a particle comprising NF-κB decoy, comprising the steps of:
A method for treating and/or preventing a disease, disorder and/or condition of the respiratory system due to expression of a gene regulated by NF-κB, comprising the step of:
A method for treating and/or preventing a disease, disorder and/or condition of the respiratory system due to an eosinophil abnormality, comprising the step of:
Use of an NF-κB decoy for the manufacture of a medicament for treating and/or preventing a disease, disorder and/or condition of the respiratory system due to expression of a gene regulated by NF-κB.
Use of an NF-κB decoy for the manufacture of a medicament for treating and/or preventing a disease, disorder and/or condition of respiratory system due to an eosinophil abnormality.
Dependencies are inferred from the claim text.